Evidence map›Paper›PMID 40396978›Full record

ArticleJournal of neuromuscular diseases2025

Short- and long-term natural history of three neurodegenerative biomarkers among middle-aged and older adults.

Rikuta Hamaya, Pamela M Rist, Varant Kupelian, Anthony L Gotter, Jihee Sohn, Carrie E Rubel, J Michael Gaziano, JoAnn E Manson, Howard D Sesso

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuromuscular diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rikuta HamayaDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Pamela M RistDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Varant KupelianBiogen, Cambridge, MA, USA.
Anthony L GotterBiogen, Cambridge, MA, USA.
Jihee SohnBiogen, Cambridge, MA, USA.
Carrie E RubelBiogen, Cambridge, MA, USA.
J Michael GazianoDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
JoAnn E MansonDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Howard D SessoDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known about the longitudinal trajectories of novel neurodegenerative biomarkers including neurofilament light (NfL), tau, and glial fibrillary acidic protein (GFAP).

objectivesWe aimed to investigate the short- and long-term natural history of these biomarkers measured longitudinally among healthy adults.

methodsIn this cohort study from the Physicians' Health Study (PHS), VITamin D and OmegA-3 TriaL (VITAL), and COcoa Supplement and Multivitamin Outcomes Study (COSMOS), we included 1299 adults with bloods collected 2 years (VITAL and COSMOS) or 14 years (PHS) apart and without diagnosed neurodegenerative diseases before baseline or during follow-up through two years after the final blood collection. Associations between baseline characteristics and changes in NfL, tau, and GFAP were evaluated.

resultsMean (SD) age at baseline was 49.8 (6.8), 67.5 (6.2), and 70.3 (5.7) in PHS, VITAL, and COSMOS, respectively. PHS enrolled only men while ∼50% of the VITAL and COSMOS populations in this study were men. Median percent changes (IQR) of NfL were 40.6% (2.4, 58.2) increase over 14 years (PHS) and 8.5% (-6.6, 28.6) over 2 years (VITAL and COSMOS); increases in tau were 101% (10.7, 285) over 14 years and 11.8% (-35.2, 106) over 2 years; and increases in GFAP were 25.1% (-1.7, 23.8) over 14 years and 5.6% (-12.8, 28.6) over 2 years. In multivariable models, age was most strongly and robustly associated with 14-year changes in NfL and GFAP (adjusted p<0.001), and increases in levels accelerated at older ages. No baseline variables were associated with changes in tau.

conclusionIncreases in NfL and GFAP accelerated with age, highlighting the need to improve our understanding of the clinical relevance of short- and long-term changes in these neurodegenerative biomarkers in large-scale, long-term cohorts.

Indexed as

Glial Fibrillary Acidic ProteinNeurodegenerative DiseasesNeurofilament Proteinstau ProteinsAgedAgingBiomarkersCohort StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedBiomarkersGFAP protein, humanGlial Fibrillary Acidic ProteinMAPT protein, humanneurofilament protein LNeurofilament Proteinstau Proteinsglial fibrillary acidic proteinnatural historyneurofilament lighttau

Identifiers

PMID40396978
PMCPMC13142827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.